Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials
Open Access
- 13 February 2018
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 21 (2)
Abstract
Initiation of antiretroviral therapy is not a once in a lifetime opportunity. In some resource constrained settings financial limitations make it necessary to prioritize treatment initiation for some groups of patients. In developed countries, there are patients who are reluctant to initiate treatment. Subgroup analysis of the START trial can inform recommendations for which patients with CD4 counts >500 cells mm3 temporary postponement of treatment initiation is safer. These include individuals aged 0.8 and/or viral load of <5000. This is because these individuals are at very low risk of disease progression in the subsequent 2 to 3 years, the risk is minimally diminished by antiretroviral therapy and is virtually identical in the first 18 months of therapy regardless of treatment initiation. In addition, asymptomatic young individuals are at higher risk of loss‐to‐follow and of low adherence to treatment, and those with low viral loads are less likely to transmit the virus. In addition, lessons from START and Temprano can help design trials to investigate strategies to decrease losses‐to‐follow‐up, while minimizing risks to patients.Keywords
This publication has 10 references indexed in Scilit:
- Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trialThe Lancet HIV, 2018
- Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trialPLOS Medicine, 2017
- Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 TargetsCurrent HIV/AIDS Reports, 2016
- Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral TherapyPLOS ONE, 2016
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in AfricaNew England Journal of Medicine, 2015
- Rating evidence in treatment guidelinesAIDS, 2013
- Credibility of claims of subgroup effects in randomised controlled trials: systematic reviewBMJ, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000